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ABSTRACT
The paper is presented essential practical knowledge about acute mucosal reactions as an effect of
radiation therapy in patients with head and neck cancers. The authors have presented their own
experience with mucosal reactions in the course of different fractionation schedules. The practical use
of Accumulated Dose in Time and Dose-Time Ratio as a parameters of the risk, intensity and overall
heaviness of radiation mucositis is proposed. .
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. Early side effects of the mucous
membrane in radiation therapy of the head and
neck cancers are generally the result of
proliferating cell death in its rapidly renewing
stem-cell and transit-cell compartments
(Kaanders and Ang, 1994). During conven-
tionally fractionated treatment, the acute
mucosal reaction is mostly within acceptable
limit. However, new radiotherapy strategies, like
hyperfractionation, accelerated fractionation and
combination of irradiation and chemotherapy,
induce more severe acute toxicity and the
mucosal reaction is elevated to the upper limit of
tolerance. Therefore, the effective and
quantitative monitoring and the knowledge about
the prevention and treatment of this side effect
are essential for further development of therapy
in head and neck cancer.
CLINICAL COURSE OF ACUTE MUCOSITIS
During radiation treatment, mucosal
erythema develops very early (within 1 week)
after the start of irradiation. The basal layer of
the epithelium shows degenerative changes, the
underlying submucosa becomes edematous with
dilatation of capillaries as an effect of
accumulation of mucous secretions in the minor
salivary glands and inflammatory reaction. At
about 2 weeks, the reddened mucous
membrane develops small white or yellow
patches of fibrin, leukocytes and necrotic
epithelium called mucositis or false membrane
formation. In many of patients, the patchy
Rep. Pract. Oncol. 1 (1) 1996
mucositis becomes confluent by the 3rd week of
irradiation and usually persists in that intensity
until the end of treatment. Mucosal healing starts
after the end of radiation and in majority of
patients all signs of mucositis disappear within 5
weeks.
Different anatomical mucosal areas
within upper aerodigestive -tract do not respond
uniformly to radiation. The soft palate, tonsillar
folds, buccal mucosa, lateral border of the
tongue, pharyngeal walls and epilarynx readily
developed mucositis than other sites, such as
hard palate, gingivas, dorsum of the tongue and
true vocal cords. Mucositis often first appears
over the tumour itself, as early as at the end of
first treatment week, especially over the
exophytic or ulcerative oropharyngeal tumour.
This early tumour reaction sharply demarcates
the area of tumour involvement and is often
called tumoritis.
FRACTIONATION SENSITIVITY
Clinical observations give evidences that
radiation mucosal reaction is sensitive to
changes in time-dose-volume relationships. At
fractionation of 2.5 Gy five times weekly
confluent mucositis is seen in all patients during
the treatment course, whereas the dose
administered at 2 Gy per fraction results in
patchy mucositis in the majority of them.
Prolongation of treatment time by introductions
of a gap during the treatment course or fraction
dose decrease to 1.6-1.8 Gy reduces mucosal
67
Skladowski et al.: Radiobiological basis, incidence....
reactions to only marked redness or small areas
of patchy mucositis. Irradiation of several
fractions (2-4) per day usually produces severe
mucosal reaction at the end of 2nd week of
treatment. On the other hand, the objective signs
of mucositis healing are not seldom seen during
the irradiation, mainly at the last week of
treatment.
This clinical evidences and results of
laboratory studies (Kaanders and Ang, 1994)
shown several importances in practice: (1) the
intensity of mucosal reaction clearly depends on
accumulation of radiation dose in time; (2) half
time of cellular repair of mucosal tissue is
around 1 hour, Le. 4-5 hours are needed for
complete repair of sublethal radiation injuries; (3)
the a/~ ratio for early mucosal reaction (4-5 Gy)
is possibly lower than for other acutely
responding normal tissues, it may suggest that
the fraction size and amount of total dose could
have a role in overall reaction heaviness; (4)
compensatory mucosal proliferation increases
over the course of fractionated irradiation and
may counteract even whole fraction dose at the'
final part of the treatment; (5) the subjective
patient complaints due to mucositis are roughly
connected with the ~mount of irradiated volume,
Le. treatment field size; (6) radioresponsiveness
(radiosensitivity?) of the mucosa is not uniform
for all anatomic sites within upper aerodigestive
tract.
KINETICS OF ACUTE MUCOSITIS
All these observations suggest that the
intensity of acute epithelial reactions, like other
H-type tissues, reflects the balance between
the rate of cell killing by radiation and the rate
of surviving stem cells regeneration . Once a
critical level of survival cells has been attained,
a certain type of clinical damage will develop at
a rate determined only by the cellular kinetics
of the mucosa. When a peak of mucositis
intensity is reached, further stem cell killing can
not produce an increase in intensity of acute
reactions, but could be manifest as prolonged
time to heal. When acute mucositis is
extremely severe, late effects, as
radionecrosis, may develop as a direct
consequence of acute injury; these are called
consequential late injuries. Consequential late
injury evolves when complete epithelial
denudation occurs with no surviving cells within
the irradiated volume such that healing, if it
occurs at all, must take place entirely by
repopulation of cells from the periphery of the
radiation field.
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UNIFORM REPORTING OF RADIATION
MUCOSITIS
Fletcher divided acute mucositis into
three grades: (1) redness, (2) spotted
mucositis and (3) confluent mucositis.
Redness was further subdivided into mild
redness and "angry red that characterizes
increasing .reaction" Le. severe redness. This
simple grading system, or its minor variations, is
still widely used and accepted (EORTC/RTOG
scale). However, in clinical practice when the
altered aggressive treatment is administered,
almost all patients reach highest, fourth, level of
mucosal radiation toxicity and further individual
differences in reaction intensity disappear.
The system proposed by Dische
(Dische, 1994) is a spread of EORTC/RTOG
glossary and places more emphasis on
functional radiation effects than on
morphological changes. The determination of
proper functional score, like grade of
odynophagia, is highly subjective and needs
well-experienced interviewer. But the expanded
range of score (- 30 points) is allowed to monitor
the differences in the individual intensity of
confluent mucositis and, perhaps, to alarm the
risk of consequential injuries.'
ACCUMULATED DOSE IN TIME
There is now a substantial number of
studies on radiotherapy for head and neck
cancer using altered fractionation schedules and
nearly all document an increased incidence and
severity of acute mucosal reactions. Thus, when
one. considers alternative fractionation
strategies, acute mucosal reactions become
most significant dose-limiting of radiation
tolerance because mucosa is very sensitive to
accumulated dose in time (ADT). Accelerated
and hyperfractionated schedules are strategies
designed to improve tumour control rate with no
or little increase of late sequelae but in aspect of
early tOXicity these strategies involve a higher
ADT than conventional treatment (Tab. I).
Analysis of the data sets of accelerated
and hyperfractionated radiation treatments
shows that, except with hyperfractionation and
short single course of accelerated regimens, the
ADT is not constant within whole treatment time.
High ADT, above 25 Gy/week (4-5 Gy/d), is
typical for accelerated treatments when the dose
is lowered and condensed into a single course
with short overall treatment time (CHART)
(Saunders et ai, 1991). In concomitant boost
schedule (Ang et ai, 1990) a high ADT of 16.5
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hypopharynx and supraglottic larynx the acute
mucosal reaction during the course and after
irradiation was investigated. All patients were in
clinical stages T2-4 NO-1, in performance status
Zubrod < 2 and have had no prior therapy. Forty
six patients were irradiated in conventional
fractionation scheme, 5 times a week with 1,8-2
Gy per fraction up to 66-72 Gy of total dose
within 45-50 days and present the control group
(A) of this study. In continuous fractionation
group (B), 47 patients were irradiated by 7 days
a week (including Saturdays and Sundays) with
1,8-2 Gy fractions up to 66-72 Gy in 33-40 days.
The 3rd (C) group including 15 patients all
fractionation parameters were like in B group
with one except that weekend breaks were
introduced but second doses were added at
Tuesdays and Fridays as a .concomitant boost.
In last group (0), 25 patients were irradiated by .
BID/split/escalated BID schedule (first 32 Gy,
two times daily 1,6 Gy fraction, then 7-12 days of
a treatment break and again 34-40 Gy two times
per day by escalated fraction dose from 1,6 to
2,0 Gy) up to 66-72 Gy in 5 weeks [Van der
Schueren et ai, 1990]. Every treatment course
has started from Monday. Acute mucosal
reaction was assessed in each patient every
Monday during the 7-week inpatient observation,
then at control follow-up visits, using the scale
proposed by Dische et al [6]. Every time when
the total score succeeded the 10 points or above
the parenteral anti-inflammatory treatment was
introduced.
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Gylweek is delivered either in begining or final
two weeks of treatment and in the remaining 4
weeks AOT is not as high as 9 Gy, or is equally
(11 Gy) distributed within the overall treatment
time. In double-BID-split course schedule [3] the
AOT of 16 Gy is given in the first 2,5 weeks and
the final 1,5 week separated by 2 weeks of
treatment break (ADT =0 Gy). As yet, the ADT
seems to be the best parameter reflecting the
rate of increase and intensity of acute radiation
effects (6,7,8).
DOSE-TIME RATIO
It is not easy, or sometimes even
impossible, to express the ADT as a single
stable value for prediction of the overall risk and
heaviness of mucosal reaction for a given
treatment schedule. For that reason, an
additional factor, Dose-Time Ratio (DTR) was
proposed to introduced to this problem. Dose-
Time Ratio is a product of ADT, Total Dose (TO)
. and number of days when irradiation is given
(Radiation Days - RD). Factor of DTR can be
written:
DTR =ADT . TD . RD
1000
and is quantified in Gl/dal. For conventional
treatment of 2 Gy per fraction, 5 times a week
(ADT = 1,43 Gy/d), up to TD of 70 Gy and 35
radiation days, the DTR is equal 3,5 Gl/d2.
Table I shows the DTR values for most
popular fractionation schemes in clinical
practice. Dose-time ratio seems to be useful to
compare different fractionation schedules in
aspect of general risk and heaviness of acute
radiation mucosal reaction, provided that
interfraction time interval is long enough for full
radiation repair (around 6 hours). Also, in our
opinion, that parameter is sufficient to predict the
risk of consequential late necrosis within the
irradiated volume.
- CONVENTIONAL FX
- - BID/SPLIT/ESC.BID FX
..... CONTINUOUS FX
--- CONCOMITANT BOOST FX
GLIWICE EXPERIENCES
Assessment of dose fractionation
factors influencing the rate of increment, peak
intensity, course and overall heaviness of acute
radiation mucosal toxicity during 4 different
fractionation schedules in radiotherapy of head
and neck cancers is the purpose of the analysis.
In 133 patients with squamous cell
carcinoma of oral cavity, oropharynx,
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Fig. 1: The comparison of the coures of acute mucosal
reaction in 4 different fractionation schedules in Gliwice
experiences.
The ADT was different between the
analysed groups of patients (1,43 Gy/d in A,
2Gy/d in Band C, and ~ 2,5 Gy/d in D). There
were no any differences in mucosal reaction
between the groups Band C in spite of weekend
treatment breaks (Fig. 1). The increase of
confluent mucositis was developed at first 2-4
weeks of treatment and its rate clearly depended
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The rate of healing of acute mucositis showed
discrete differences between the analysed
groups of patients and was independent on
overall treatment time. The process of mucosal
healing seems to be associated rather with
overall heaviness of mucosal reaction i.e. high
values of DTR and risk of consequential necro-
sis; in group BIC consequential soft tissue or bo-
ne necrosis occurred in 5 patients (8%) compare
to 1 patient (2%) with necrosis in group A.
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Figure 2A: The relationship between the rate of mucositis
intensity estimated in Gliwice study and Accumulated Dose
in Time (ATD).
Figure 28: The relationship between the overall heaviness
ad acute mucosal reaction estimated in Gliwice experiences
and Dose-Time Ratio (DTR).
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on ADT, as well as, the peak of intensity (Fig.
2A). Also the time when mucositis reached the
maximum score was different between the
groups: second and half week in D versus 4th
week in A-C (Fig. 1). The introduction of
treatment gap in D schedule allowed severe
confluent mucositis to partial healing before the
second part of treatment, but the second wave
of intensity was lower than that associated with
first part of irradiation in spite of increasing ADT.
The overall heaviness of radiation reaction
(estimated in this study as an area under the
curves) in group BIC and D was ~ 50% and ~
25% respectively more severe than in control
group A and this data were consistent with the
comparison of DTRs of groups BIC and D to
group A (Fig. 2B).
Table I. The values of Accumulated Dose in Time (ADT) and Dose-Time Ratio (DTR) for most popular
fractionation schedules.








Concomitant boost [4] 72Gy/42Fxl40days
Gliwice StUdy
Continuous (B) 70,2Gy/39Fxl39days
Concomitant boost (C) 70,2Gy/39Fxl39days
BID/SPLITlESC-BID (D) 70Gy/41 Fxl36days












(*) Manchester school, (#) Gliwice experiences
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Our study suggests that: (1) the rate of
increasing acute mucosal reaction depends on
accumulated dose in time; (2) the rate of its
healing and risk of consequential late effects
seems to be dependent on overall heaviness of
mucositis what correlated with high value of
DTR in our study; (3) treatment gaps allow the
partial healing what diminishes the intensity of
mucositis in renewal irradiation; (4) precise
scoring and monitoring system of acute mucosal
reaction is essential in clinical practice and can
help to avoid severe postradiation complications
in patients with head and neck Cancer.
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